June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The Use of PolyChromatic Angiography for the Assessment of the Effects of VEGF and Bevacizumab on the Rabbit Retina
Author Affiliations & Notes
  • Samir Tari
    PCAsso Diagnostics, North Brunswick, NJ
  • C. Michael Samson
    New York Eye and Ear Infirmary, New York, NY
  • Uday Kompella
    University of Colorado Denver, Denver, CO
  • Robert Harris
    Rutgers University, New Brunswick, NJ
  • Cheng-mao Lin
    University of Michigan, Ann Arbor, MI
  • David Antonetti
    University of Michigan, Ann Arbor, MI
  • Gaetano Barile
    Manhattan Eye Ear and Throat Hospital, New York, NY
  • Footnotes
    Commercial Relationships Samir Tari, PCAsso Diagnostics LLC (I), PCAsso Diagnostics LLC (E), PCAsso Diagnostics LLC (P); C. Michael Samson, CLS Pharmaceuticals (I), PCAsso (I); Uday Kompella, University of Colorado Denver (P), PCAsso Diagnostics (C), NanoTrans Technologies, Inc. (F), Univesity of Nebraska Medical Center (P); Robert Harris, PCAsso Diagnostics (F); Cheng-mao Lin, None; David Antonetti, None; Gaetano Barile, PCAsso Diagnostics LLC (P), PCAsso Diagnostics LLC (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5820. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samir Tari, C. Michael Samson, Uday Kompella, Robert Harris, Cheng-mao Lin, David Antonetti, Gaetano Barile; The Use of PolyChromatic Angiography for the Assessment of the Effects of VEGF and Bevacizumab on the Rabbit Retina. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5820.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the utility of PolyChromatic Angiography (PCA) in the assessment of the response to different doses VEGF and bevacizumab .

 
Methods
 

Twenty six eyes of twenty four Dutch Belted rabbits were injected intravitreally with 1.25 µg (group A, n=5), 4 µg (Group B, n=6) and 10 µg (Group C, n=7), 4 µg (Group D, n=4) and 4 µg (Group E, n=4) VEGF on day 0. Groups D and E were also injected intravitreally with 1.25 µg and 12.5 µg bevacizumab, respectively, on day 2. On days 0,2,4,7, 11 and 14 PCA was performed using a contrast agent mixture composed of fluorescein sodium, Indocyanine green, PCM102 and PCM 107 and imaged by a modified TRC 50 VT fundus camera. PCA scores were given based on leaking fluorophores.

 
Results
 

On day 7, there was a statistically significant difference between group A (0.6 ±0.89, PCA Score± st. dv.) and both groups B (2.67± 1.37, p value = 0.0154) and C ( 3.33 ±0.52, p value = 0.00085). There was also a statistically significant difference between groups B and E (PCA score 0.75 ± 0.96, p value = 0.032) on day 7. On day 11, there was statistically significant difference between group C (1.80±1.1) and both groups A (0, p value=0.021) and B (0.33±0.52, p value= 0.037).

 
Conclusions
 

PCA is a useful tool for the assessment and grading of BRB dysfunction in the rabbit retina. PCA may become a useful diagnostic tool for grading disease severity in patients with similar pathologies.

 
 
PCA scores before, 2, 4 7 11 and 14 days after intravitreal VEGF injection in rabbits. Mean ± Standard deviation. * p≤0.05, **p≤0.001.
 
PCA scores before, 2, 4 7 11 and 14 days after intravitreal VEGF injection in rabbits. Mean ± Standard deviation. * p≤0.05, **p≤0.001.
 
 
PCA scores before, 2, 4 7 11 and 14 days after intravitreal VEGF± bevacizumab injection in rabbits. Mean ± Standard deviation. * p=0.032, #p=0.08.
 
PCA scores before, 2, 4 7 11 and 14 days after intravitreal VEGF± bevacizumab injection in rabbits. Mean ± Standard deviation. * p=0.032, #p=0.08.
 
Keywords: 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 700 retinal neovascularization • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×